A detailed history of Cibc Asset Management Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Cibc Asset Management Inc holds 19,437 shares of IBRX stock, worth $47,037. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,437
Previous 18,704 3.92%
Holding current value
$47,037
Previous $118,000 38.98%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$3.32 - $6.7 $2,433 - $4,911
733 Added 3.92%
19,437 $72,000
Q2 2024

Aug 01, 2024

BUY
$4.82 - $9.15 $90,153 - $171,141
18,704 New
18,704 $118,000
Q4 2022

Feb 13, 2023

SELL
$4.35 - $6.77 $19,609 - $30,519
-4,508 Reduced 28.77%
11,161 $56,000
Q2 2022

Aug 09, 2022

SELL
$2.68 - $6.14 $3,071 - $7,036
-1,146 Reduced 6.82%
15,669 $58,000
Q4 2021

Feb 08, 2022

BUY
$5.67 - $10.18 $6,985 - $12,541
1,232 Added 7.91%
16,815 $102,000
Q3 2021

Nov 09, 2021

BUY
$9.17 - $14.24 $142,896 - $221,901
15,583 New
15,583 $152,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $969M
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Cibc Asset Management Inc Portfolio

Follow Cibc Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.